Structural changes by sulfoxidation of phenothiazine drugs

SummaryThe side-chain conformations of psychoactive phenothiazine drugs in crystals are different from those of biologically inactive ring sulfoxide metabolites. This study examines the potential energies, molecular conformations and electrostatic potentials in chlorpromazine, levomepromazine (methotrimeprazine), their sulfoxide metabolites and methoxypromazine. The purpose of the study was to examine the significance of the different crystal conformations of active and inactive phenothiazine derivatives, and to determine why phenothiazine drugs lose most of their biological activity by sulfoxidation. Quantum mechanics and molecular mechanics calculations demonstrated that conformations with the side chain folded over the ring structure had lowest potential energy in vacuo, both in the drugs and in the sulfoxide metabolites. In the sulfoxides, side chain conformations corresponding to the crystal structure of chlorpromazine sulfoxide were characterized by stronger negative electrostatic potentials around the ring system than in the parent drugs. This may weaken the electrostatic interaction of sulfoxide metabolites with negatively charged domains in dopamine receptors, and cause the sulfoxides to be virtually inactive in dopamine receptor binding and related pharmacological tests.

[1]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[2]  I. Sylte,et al.  Three-dimensional structure and molecular dynamics of cis(Z)- and trans(E)-chlorprothixene. , 1991, Journal of pharmaceutical sciences.

[3]  P. Rossky,et al.  Molecular conformational equilibria in liquids , 1986 .

[4]  P. Kollman,et al.  An all atom force field for simulations of proteins and nucleic acids , 1986, Journal of computational chemistry.

[5]  S. Dahl,et al.  Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. , 1986, Biochemical pharmacology.

[6]  Conrad C. Huang,et al.  The MIDAS database system , 1988 .

[7]  Conrad C. Huang,et al.  The MIDAS display system , 1988 .

[8]  H. Refsum,et al.  Effects of levomepromazine, chlorpromazine and their sulfoxides on isolated rat atria. , 1976, European journal of pharmacology.

[9]  I. Sylte,et al.  Molecular dynamics of dopamine at the D2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  F M Richards,et al.  Areas, volumes, packing and protein structure. , 1977, Annual review of biophysics and bioengineering.

[11]  S. Dahl.  Active metabolites of phenothiazine drugs , 1981 .

[12]  Louis Pierce,et al.  Microwave Spectrum, Dipole Moment, Structure, and Internal Rotation of Dimethyl Sulfide , 1961 .

[13]  L. Gottschalk,et al.  Plasma concentrations of thioridazine metabolites and ECG abnormalities. , 1978, Journal of pharmaceutical sciences.

[14]  S. Abrahams.  The crystal structure of dpihenyl sulfoxide , 1957 .

[15]  K. Midha,et al.  Radioimmunoassay for the sulfoxide metabolite of trifluoperazine and its application to a kinetic study in humans. , 1984, Journal of pharmaceutical sciences.

[16]  P. Kollman,et al.  An approach to computing electrostatic charges for molecules , 1984 .

[17]  S. Dahl,et al.  Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation. , 1982, Molecular Pharmacology.

[18]  M. L. Connolly.  Solvent-accessible surfaces of proteins and nucleic acids. , 1983, Science.

[19]  S. Snyder,et al.  3H-Haloperidol binding to dopamine receptors in rat corpus striatum: influence of chlorpromazine metabolites and derivatives. , 1978, European journal of pharmacology.

[20]  J. Feeney,et al.  Binding of flexible ligands to macromolecules , 1975, Nature.

[21]  S. Abrahams,et al.  The crystal structure of di‐p‐tolyl telluride , 1955 .

[22]  J. J. H. McDowell,et al.  The crystal and molecular structure of chlorpromazine , 1969 .

[23]  S. Dahl.  Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects , 1982, Therapeutic drug monitoring.

[24]  L. Iversen,et al.  The Action of Neuroleptic Drugs on Dopamine-Stimulated Adenosine Cyclic 3',5'-Monophosphate Production in Rat Neostriatum and Limbic Forebrain , 1974 .

[25]  S. Dahl,et al.  Pharmacokinetics of chlorpromazine after single and chronic dosage , 1977, Clinical pharmacology and therapeutics.

[26]  P. Marsau,et al.  Structure cristalline de dérivés de la phénothiazine. V. Méthoxypromazine , 1973 .

[27]  K. Neve,et al.  Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. , 1991, Molecular pharmacology.